Antiemesis

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 5, 2009, Pages 572-595

  Ettinger, David S ^a   Armstrong, Debra K ^a   Barbour, Sally ^a   Berger, Michael J ^a   Bierman, Philip J ^a   Bradbury, Bob ^a   Ellis, Georgianna ^a   Kirkegaard, Steve ^a   Kloth, Dwight D ^a   Kris, Mark G ^a   Lim, Dean ^a   Markiewicz, Michael Anne ^a   Nabati, Lida ^a   Nesheiwat, Carli ^a   Rugo, Hope S ^a   Sorscher, Steven M ^a   Stucky Marshal, Lisa ^a   Todaro, Barbara ^a   Urba, Susan ^a  

^a NONE

Author keywords

5 HT3 receptor antagonists; Antiemesis; Chemotherapy induced; Nausea and vomiting; NCCN Clinical Practice Guidelines; NK 1 receptor antagonists

Indexed keywords

ALPRAZOLAM; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; DRONABINOL; ETOPOSIDE; FOSAPREPITANT; GRANISETRON; HALOPERIDOL; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; NABILONE; NAVELBINE; OLANZAPINE; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN ANTAGONIST; UNINDEXED DRUG; WARFARIN;

ACUTE DISEASE; ADD ON THERAPY; ANTICIPATORY NAUSEA AND VOMITING; ANXIETY DISORDER; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HUMAN; NAUSEA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RADIATION INDUCED EMESIS; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING; ALGORITHM; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; RADIOTHERAPY; RISK ASSESSMENT;

ALGORITHMS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NAUSEA; RADIOTHERAPY; RISK ASSESSMENT; VOMITING;

EID: 66749129673     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0039     Document Type: Review

References (117)

1. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. Antiemetics and Cancer Chemotherapy. Baltimore: Williams & Wilkins; 1983:1-5.
2. Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 1984;11:97-102.
3. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566-579.
4. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;5:1746-1752.
5. Morran C, Smith DC, Anderson DA, et al. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1979;1:1323-1324.
6. Jenns K. Importance of nausea. Cancer Nurs 1994;17:488-493.
7. Nesse RM, Carli T, Curtis GC et al. Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 1980;42:33-36.
8. Wilcox PM, Fetting JH, Nettesheim KM, et al. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 1982;66:1601-1604.
9. Carey MP, Burish TG. Anxiety as a predictor of behavioral therapy outcome for cancer chemotherapy patients. J Consult Clin Psychol 1985;53:860-865.
10. Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manag 1991;6:215-223.
11. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-772.
12. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34-44.
13. Borison HL, Wang S. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193-230.
14. Siegel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352-359.
15. Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 1985;10:143-166.
16. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-1384.
17. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991;14:238-242.
18. Moher D, Arthur AZ, Peter JL. Anticipatory nausea and/or vomiting in chemotherapy patients. Cancer Treat Rev 1984;11:257-264.
19. Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-336.
20. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-1176.
21. Harding RK, Young RW, Anno GH. Radiotherapy-induced emesis. In: Andrews PLR, Sanger GJ, eds. Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical; 1993:163-178.
22. Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28.
23. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
24. Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 1982;9:3-9.
25. Strum SB, McDermed JE, Pileggi J, et al. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 1984;53:1432-1439.
26. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7:1142-1149.
27. Aapro MS. Methodological issues in anti-emetic studies. Invest New Drugs 1993;11:243-253.
28. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
29. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005;13:80-84.
30. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002;10:519-522.
31. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-620.
32. Andrews PL, Bhandari P, Davey PT, et al. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992;28A(Suppl 1):S2-6.
33. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297-2303.
34. Grunberg SM, Stevenson LL, Russell CA, et al. Dose-ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-1141.
35. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexametliasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990;26:S33-36.
36. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26:S23-27.
37. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834-840.
38. Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26(Suppl 1):S28-32.
39. Marty M, Pouillart P, School S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.
40. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26(Suppl 1):S15-19.
41. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-678.
42. Fraschini G. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol 1992;19(4 Suppl 10):S41-47.
43. Kamanabrou D. Intravenous granisetron establishing the optimal dose. Eur J Cancer 1992;28A(Suppl 1):S6-11.
44. Sledge GW Jr, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70:2524-2528.
45. Chevallier B. The control of acute cisplatin-induced emesis - a comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993;68:176-180.
46. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-HT antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204-2210.
47. Riviere A. Dose-finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967-971.
48. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482.
49. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 2007;3:1009-1020.
50. Grunberg S, Gabrial N, Clark G. Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy [Abstract]. MASCC/ISOO 20th Anniversary International Symposium Supportive Care in Cancer; St. Gallen, Switzerland; June 27-30, 2007:687. Astract P-18.
51. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
52. Bonneterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A crossover study. Bull Cancer 1995;82:1038-1043.
53. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 1992;31:573-575.
54. Jantunen IT, Muhonen TT, Kataja W, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 1993;29A:1669-1672.
55. Martoni S, Angelelli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study. Am Soc Lin Oncol 1993;13:431.
56. Campora LE, Simoni C, Rosso R. [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma]. Minerva Med 1994;85:25-31 [in Italian].
57. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994;74:1945-1952.
58. Mantovani A, Maccio L, Curreli L, et al. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. Proc Am Soc Clin Oncol 1994;13:428.
59. Massidda B, Laconi S, Foddi MR, et al. Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT receptors. Ann Oncol 1994;5:S204.
60. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30:1083-1088.
61. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994;51:113-118.
62. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805-810.
63. Marty M, Kleisbauer JP, Fournel P, et al. Is navoban (tropisetron) as effective as zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995;6(Suppl 1):S15-21.
64. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248.
65. Stewart A, McQuade B, Cronje JDE, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: a multi-centre, double-blind, double dummy, randomised, parallel-group study. Oncology 1995;52:202-210.
66. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813.
67. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondaneston for the prevention of amesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer 1996;32A:1523-1529.
68. Hesketh PJ, Navari R, Grote T, et al. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249.
69. Leonardi V, Iannitto E, Meli M, Palmeri S. Ondansetron vs granisetron in the control of chemotherapy-induced acute emesis: a multicenter randomized trial. Oncology Rep 1996;3:919-923.
70. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron, and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-2973.
71. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15:1023-1033.
72. Huang JQ, Zheng GF, Deuson R, et al. Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [Abstract]. J Clin Oncol 2004;22:Abstract 6037.
73. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300.
74. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
75. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-410.
76. Warr DG, Eisenberg P, Hesketh PJ, et al. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients [Abstract]. J Clin Oncol 2004;22:Abstract 8007.
77. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830.
78. Gralla RJ, Warr DG, Carides AD, et al. Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from 2 phase III randomized clinical trials [abstract]. J Clin Oncol 2004;22:Abstract 8137.
79. Tremont-Lukats IW, González-Barboteo J, Bruera E, et al. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol 2004;22:Abstract 8047.
80. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-408.
81. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-223.
82. Emend [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2003. Available at: http://www.fda.gov/cder/foi/label/2008/021549s015lbl.pdf. Accessed April 7, 2009.
83. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983;25:31-51.
84. Gralla RJ, Braun TJ, Itri LM, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-909.
85. Gralla RJ, Tyson LB, Borden LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984;68:163-172.
86. Bakowski MT. Advances in anti-emetic therapy. Cancer Treat Rev 1984;11:237-256.
87. Grossman B, Lessen LS, Cohen P. Droperidol prevents nausea and vomiting from cisplatinum (letter). N Engl J Med 1979;301:7.
88. Aapro MS, Alberts DS. High dose dexamethasone for prevention of cisplatinum-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-14.
89. Aapro, MS, Plezia, PM, Alberts, DS, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984;2:466-471.
90. Cassileth PA, Lusk EJ, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving chemotherapy. Arch Intern Med 1983;143:1347-1349.
91. Kris MG, Gralla RJ, Clark RA, et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 1985;69:1257-1262.
92. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 1987;69:1353-1357.
93. Herman TS, Einhorn LH, Jones SE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;200:1295-1297.
94. Steele N, Gralla RJ, Braun DW, et al. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219-224.
95. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol 2004;22:Abstract 8046.
96. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529-534.
97. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25:578-582.
98. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004;22:383-388.
99. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25:485-488.
100. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23:526-532.
101. Morita T, Tei Y, Shishido H, et al. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage 2004;28:102-103.
102. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-124.
103. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294.
104. Massa E, Astara G, Madeddu C, et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 2009;70:83-91.
105. Franzen L, Nyman J, Hagberg H, et al. A randomized placebo-controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996;7:587-592.
106. Wong RK, Paul N, Ding K, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006;24:3458-3464.
107. Belkacemi Y, Ozsahim M, Pene F, et al. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiation Oncol Biol Phys 1996;36:77-82.
108. Okamoto S, Takahashi S, Tanosaki R, et al. Granisetron in the prevention of vomiting induced conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996;17:679-683.
109. Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005;23:7188-7198.
110. Morrow GR, Morrell C. Behavioral treatment for the anticipating nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476-1480.
111. Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982;50:1018-1029.
112. Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of alprazolam. J Clin Oncol 1993;11:1384-1390.
113. th ed. Montvale, NJ: Thomson PDR; 2004. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 5816#nlm34068-7. Accessed April 7, 2009.
114. Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2008;2:28-34.
115. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-116.
116. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-59.
117. Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007;15:417-426.